{Reference Type}: Journal Article
{Title}: Oncolytic vaccinia virus harboring CLEC2A gene enhances viral replication and antitumor efficacy.
{Author}: Gao C;Ying Q;Qiu Y;Ren N;Chen K;Zhou Y;Ye T;Li G;
{Journal}: Mol Ther Oncol
{Volume}: 32
{Issue}: 3
{Year}: 2024 Sep 19
暂无{DOI}: 10.1016/j.omton.2024.200823
{Abstract}: In the field of innovative cancer treatment strategies, oncolytic vaccinia virus (VV)es have gained traction as promising vectors. In the current study, we inserted the human C-type lectin domain family 2 member A (CLEC2A) gene into VV, creating a replicating therapeutic, oncoVV-CLEC2A. The findings reveal that oncoVV-CLEC2A effectively suppresses colorectal proliferation of mouse xenografts and a range of human cancer cell lines by augmenting viral reproduction capabilities, including the lung cancer H460 cell line, colorectal cancer cell lines (HCT116 and SW620), and hepatocellular carcinoma HuH-7 cell line. Moreover, it is evident that oncoVV-CLEC2A can induce antitumor immunity by boosting cytokine production but not antivirus response, and enhancing calreticulin expression. Further investigation indicates that oncoVV-CLEC2A can enhance antitumor capabilities by activating natural killer cells to produce interferon-γ and induce M1-like macrophage polarization. These findings shed light on the antitumor mechanisms of oncoVV-CLEC2A, provide a theoretical basis for oncolytic therapies, and lay the groundwork for novel strategies for modifying VVs.